Syndrome News and Research

RSS

Neural mechanisms of fatigue in COVID-19 convalescents

In a recent study posted to the medRxiv* preprint server, researchers characterized the mechanisms associated with neural dysregulation in post-coronavirus disease (COVID) fatigue (pCF) by evaluating individuals recovered from mild severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.

23 Feb 2022

SARS-CoV 2 Omicron prevalent in vaccine breakthrough cases in Bahia, Brazil

In a recent study posted to the medRxiv* pre-print server, researchers performed genomic monitoring to estimate the magnitude and range of the different severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern (VOCs) in SARS-CoV-2 reinfection cases among fully vaccinated individuals in Salvador, Bahia, Brazil.

23 Feb 2022

Low risk of second allergic reaction after SARS-CoV-2 vaccination

In a recent investigation posted to the journal JAMA Internal Medicine,* researchers estimate the risk of a repeated allergic reaction to the second severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) messenger ribonucleic acid (mRNA) vaccine dose in those with a history of allergic responses following the first dose by conducting a systematic review and meta-analysis.

22 Feb 2022

Circulating miR-155 may predict chances of survival in hospitalized COVID-19 patients

Scientists from Israel have recently estimated the levels of circulating microRNAs (miRNAs) in hospitalized coronavirus disease 2019 (COVID-19) patients with the aim of identifying prognostic biomarkers for disease severity. They have identified miR-155, an important regulatory molecule in the immune system, as a potential biomarker to predict COVID-19 severity and mortality.

22 Feb 2022

Omicron neutralizing titers after third BNT162b2 dose are persistent

The new study, published in the journal Cell Host and Microbe, also finds that the neutralization against Omicron remains robust at four months after the third dose of the BNT162b2 vaccine.

22 Feb 2022

Study shows Pfizer-BioNTech booster protects over 65s against Delta and Omicron

New research in nursing home residents found that a third dose of the Pfizer-BioNTech COVID-19 vaccine was effective for at least three months in protecting against the Delta and Omicron variant. While two doses of an mRNA COVID-19 vaccine showed poor neutralization to Omicron than Delta, a booster shot increased neutralizing antibody responses.

22 Feb 2022

Syndrome News and Research

Neural mechanisms of fatigue in COVID-19 convalescents

SARS-CoV 2 Omicron prevalent in vaccine breakthrough cases in Bahia, Brazil

Low risk of second allergic reaction after SARS-CoV-2 vaccination

Circulating miR-155 may predict chances of survival in hospitalized COVID-19 patients

Omicron neutralizing titers after third BNT162b2 dose are persistent

Study shows Pfizer-BioNTech booster protects over 65s against Delta and Omicron

Pre-existing B-cell immunity against SARS-CoV-2 not detected in pre-pandemic samples

Role of SARS-CoV-2 seroprevalence studies in disease surveillance

CD91 receptor promotes SARS-CoV-2 infection

Poor sleep increases severity of viral respiratory infections including COVID-19

Exploring the potential of mosaic RBD nanoparticles to fight SARS-CoV-2

Breath tests can help detect traces of SARS-CoV-2 virus

Cellular automata imaging-based classification of SARS-CoV-2 variants

Study explores the decline in viral load and immune response in COVID-19 patients

SARS-CoV-2 Omicron variant rapidly takes over Delta viral strain in Norwegian households

Assessing the transmissibility of SARS-CoV-2 variants of concern

Severity of SARS-CoV-2 infections with Omicron BA.2 variant relative to the BA.1 variant in South Africa

REGEN-COV antibody combination to prevent COVID-19 severity

Study provides a potent biparatopic antibody against all SARS-CoV-2 variants of concern

Prevalence of chemosensory loss induced by SARS-CoV-2 Omicron variant in Italy

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Inside the Alzheimer's Association: Dr. Heather Snyder on Driving Research and Collaboration

Latest News